BCL9 and neoplasm: Currently, a growing quantity of research initiatives have concentrated on medications that are protein-protein interaction inhibitors that disrupt interactions between β-catenin and Bcl9 in the tumor Wnt/β-catenin pathway in an attempt to uncover promising candidates for enhancing immunity and inhibiting tumor growth (89).